Aspire Biopharma Holdings, Inc. 8-K

What Happened

• Aspire Biopharma Holdings, Inc. (ASBP) reported entering into and closing financings under a Securities Purchase Agreement for newly‑designated Series A Convertible Preferred Stock. The financing included two closings: an initial issuance of 13,750 preferred shares for aggregate gross proceeds of $11.0 million (including $943,801 of converted debt) and a second closing on April 15, 2026 issuing 12,500 preferred shares for $10.0 million. The Company filed a Certificate of Amendment on April 13, 2026 to clarify and restate the Series A designation and to designate 30,000 shares of Series A Convertible Preferred Stock (stated value $1,000 per share).
• The preferred shares are convertible into common stock at the holder’s option under the Certificate of Designation, with the conversion price set at 80% of the lowest closing price of the common stock over a five‑trading‑day lookback (subject to a floor tied to Nasdaq rules and other adjustments). Conversion is immediate but subject to a beneficial‑ownership cap (initially 4.99%, adjustable up to 9.99% with notice and a 61‑day delay). Shareholder approval for conversion above 19.99% was obtained on April 10, 2026. RBW Capital Partners served as placement agent and was paid a $900,000 fee.

Key Details

• Financing closings: 13,750 shares for $11.0M (incl. $943,801 debt conversion) and 12,500 shares for $10.0M; roughly $21.0M aggregate proceeds as reported.
• Preferred designation amended April 13, 2026 to 30,000 shares, par $0.0001, stated value $1,000 per share.
• Conversion terms: conversion price = 80% of the lowest closing price over the prior 5 trading days (subject to a Nasdaq‑based floor); conversion cap initially limits beneficial ownership to 4.99% per investor (adjustable up to 9.99% with delay).
• Company states it believes stockholders’ equity now exceeds the $2.5M minimum for continued Nasdaq Capital Market listing and is awaiting formal Nasdaq confirmation.

Why It Matters

• Dilution and conversion mechanics: These preferred shares can convert into common stock at a material discount (80% of a short lookback), which could meaningfully increase share count if converted. The beneficial‑ownership caps limit immediate large takeovers via conversion but can be raised, which investors should monitor.
• Capital and listing impact: The reported proceeds improve near‑term liquidity and, according to the company, bring stockholders’ equity above Nasdaq’s minimum threshold — a key factor for maintaining listing. Investors should watch for Nasdaq’s formal confirmation and any further issuances or conversions that affect outstanding common shares.